Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study

BACKGROUND: Gefitinib is recommended as a first-line treatment option for elderly patients with non-small cell lung cancer (NSCLC). Because no pharmacokinetics of gefitinib have been examined, we prospectively assessed the pharmacokinetics of gefitinib in patients with epidermal growth factor recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Nio, Yuta, Ishida, Hiroo, Matsumoto, Natsumi, Kusumoto, Sojiro, Kubota, Yutaro, Tsunoda, Takuya, Sasaki, Yasutsuna, Fujita, Ken-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710131/
https://www.ncbi.nlm.nih.gov/pubmed/36451169
http://dx.doi.org/10.1186/s12890-022-02249-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710131/
https://www.ncbi.nlm.nih.gov/pubmed/36451169
http://dx.doi.org/10.1186/s12890-022-02249-8

Ejemplares similares